PTC Therapeutics: Mark Elliott Boulding sells 2,812 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
PTC Therapeutics, Inc. (PTCT) EVP and CLO Mark Elliott Boulding exercised options for 2,812 common shares at $25.69 per share on November 16, 2026, then sold 2,812 shares in three reported sale lots: 1,315 at a weighted average $61.39, 1,288 at $62.22, and 209 at $62.90 per share. The sale prices were weighted averages across multiple trades. The transactions were made under a written Rule 10b5-1 plan adopted September 10, 2025. After the exercise, the reported option position was 14,064 shares, with an expiration date of February 14, 2034.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F5 | 2,812 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 2,812 | $25.69 | $72K |
| Sale | Common Stock F1, F2 | 1,315 | $61.39 | $81K |
| Sale | Common Stock F1, F3 | 1,288 | $62.22 | $80K |
| Sale | Common Stock F1, F4 | 209 | $62.90 | $13K |
Footnotes (5)
- F1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.
- F2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $60.87 to $61.76 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F3. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $61.89 to $62.62 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F4. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $62.90 to $63.00 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F5. This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.
Key Figures
Key Terms
Rule 10b5-1 plan regulatory
weighted average price financial
exercise price financial
vests over four years financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.